CN102159247A - 药物载体 - Google Patents

药物载体 Download PDF

Info

Publication number
CN102159247A
CN102159247A CN2008801311871A CN200880131187A CN102159247A CN 102159247 A CN102159247 A CN 102159247A CN 2008801311871 A CN2008801311871 A CN 2008801311871A CN 200880131187 A CN200880131187 A CN 200880131187A CN 102159247 A CN102159247 A CN 102159247A
Authority
CN
China
Prior art keywords
therapeutic composition
carrier
therapeutic
cationic polymeric
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801311871A
Other languages
English (en)
Chinese (zh)
Inventor
新津洋司郎
俞磊
赵刚
桑·范
陈辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of CN102159247A publication Critical patent/CN102159247A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801311871A 2008-07-30 2008-09-12 药物载体 Pending CN102159247A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US8497708P 2008-07-30 2008-07-30
US8496408P 2008-07-30 2008-07-30
US8494708P 2008-07-30 2008-07-30
US8493908P 2008-07-30 2008-07-30
US8496808P 2008-07-30 2008-07-30
US8495508P 2008-07-30 2008-07-30
US61/084,955 2008-07-30
US61/084,977 2008-07-30
US61/084,947 2008-07-30
US61/084,939 2008-07-30
US61/084,968 2008-07-30
US61/084,964 2008-07-30
PCT/US2008/076295 WO2010014117A1 (en) 2008-07-30 2008-09-12 Drug carriers

Publications (1)

Publication Number Publication Date
CN102159247A true CN102159247A (zh) 2011-08-17

Family

ID=40627040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801311871A Pending CN102159247A (zh) 2008-07-30 2008-09-12 药物载体

Country Status (11)

Country Link
US (2) US20100028416A1 (cg-RX-API-DMAC7.html)
EP (1) EP2323693B1 (cg-RX-API-DMAC7.html)
JP (3) JP2011529492A (cg-RX-API-DMAC7.html)
KR (2) KR20110051214A (cg-RX-API-DMAC7.html)
CN (1) CN102159247A (cg-RX-API-DMAC7.html)
AU (1) AU2008359989A1 (cg-RX-API-DMAC7.html)
CA (1) CA2732412C (cg-RX-API-DMAC7.html)
ES (1) ES2657214T3 (cg-RX-API-DMAC7.html)
RU (2) RU2505315C2 (cg-RX-API-DMAC7.html)
TW (1) TW201004646A (cg-RX-API-DMAC7.html)
WO (1) WO2010014117A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736179A (zh) * 2012-05-07 2015-06-24 日东电工株式会社 具有接头的聚合物缀合物
CN104780911A (zh) * 2012-10-30 2015-07-15 粒子科学有限公司 具有靶向部分的药物递送粒子制剂
CN106133024A (zh) * 2014-04-07 2016-11-16 日东电工株式会社 用于疏水性药物递送的新颖的基于聚合物的助水溶物
CN112004528A (zh) * 2017-12-18 2020-11-27 巴德股份有限公司 载药微珠组合物、栓塞组合物和相关方法
US11590080B2 (en) 2017-12-18 2023-02-28 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
US12558308B2 (en) 2017-12-18 2026-02-24 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
JP5744723B2 (ja) * 2008-09-12 2015-07-08 日東電工株式会社 線維性疾患のイメージング剤
CA2781896C (en) 2009-12-09 2021-03-30 Nitto Denko Corporation Modulation of hsp47 expression
IN2013CN00342A (cg-RX-API-DMAC7.html) * 2010-06-17 2015-07-03 Nitto Denko Corp
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CN102652835A (zh) * 2010-12-10 2012-09-05 邹长坪 缓释高分子维甲酸
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Hsp47表現調控強化用類視色素脂質體
CN107043334B (zh) * 2011-06-08 2020-06-16 日东电工株式会社 用于定向药物输送和增强siRNA活性的化合物
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
US20140315975A1 (en) 2011-06-21 2014-10-23 Nitto Denko Corporation Apoptosis-inducing agent
IN2014MN00908A (cg-RX-API-DMAC7.html) * 2011-11-18 2015-04-17 Nitto Denko Corp
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
CN105143244A (zh) * 2013-04-26 2015-12-09 日东电工株式会社 降低多聚阴离子聚合物偶联物中的内毒素
KR102091588B1 (ko) * 2013-05-27 2020-03-24 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 점액 분산 또는 수화용 조성물
EP2823811A1 (en) * 2013-07-09 2015-01-14 OTC GmbH Targeted active release system comprising solid lipid nano-particles
US20160193249A1 (en) * 2013-09-03 2016-07-07 William Marsh Rice University Treatment of inflammatory diseases by carbon materials
US11430024B2 (en) * 2013-09-04 2022-08-30 Amos M. Cohen System and method of providing a virtual guestbook
WO2015087083A1 (en) * 2013-12-13 2015-06-18 Cipla Limited Intranasal pharmaceutical compositions of polymeric nanoparticles
JP6602034B2 (ja) 2014-04-02 2019-11-06 日東電工株式会社 標的化分子およびその使用
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤
RU2575925C1 (ru) * 2014-11-06 2016-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Тетравалентные неогликоконъюгаты с углеводным разветвляющим ядром и способ их получения
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
US11253598B2 (en) * 2015-09-15 2022-02-22 Samyang Holdings Corporation Pharmaceutical composition containing anionic drug, and preparation method therefor
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2703624C2 (ru) * 2017-11-10 2019-10-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Коаксиальные регулярные нано-мезоструктуры, способ их получения и способ получения микрокапсул из этих структур
KR20200087594A (ko) * 2019-01-11 2020-07-21 한국화학연구원 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
WO2021053163A1 (en) 2019-09-19 2021-03-25 Danmarks Tekniske Universitet Immune stimulating micelle composition
WO2021067914A1 (en) * 2019-10-03 2021-04-08 The Trustees Of Columbia University In The City Of New York Combination therapy for acute myeloid leukemia, myelodysplastic syndromes and other blood diseases and disorders
KR20220128568A (ko) * 2021-03-12 2022-09-21 주식회사 엑소스템텍 비타민 a로 표면개질된 엑소좀을 포함하는 간 섬유증 예방 또는 치료용 약학적 조성물

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1995025764A1 (en) * 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Double-stranded derivative of polyoxyethylene-containing lipid
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6033849A (en) * 1995-05-26 2000-03-07 The Salk Institute For Biological Studies Method for isolation of extrachromosomal amplified genes
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ZA972087B (en) * 1996-03-15 1997-10-24 Theratech Inc Targeting macromolecular produgs to T lymphocytes.
JP2001505529A (ja) * 1996-03-20 2001-04-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Her―2/neuを過剰発現する癌細胞の化学療法への感作
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6683048B1 (en) * 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
AU1124499A (en) * 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) * 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
EP1140106B1 (en) * 1998-12-18 2005-08-03 Scios Inc. Treatment of diseases involving cyst formation
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
FR2790405B1 (fr) * 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6663606B1 (en) * 1999-10-28 2003-12-16 Scimed Life Systems, Inc. Biocompatible medical devices
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
AU2001227756A1 (en) * 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
AU2001261031A1 (en) * 2000-04-17 2001-10-30 Childrens Hospital Research Foundation Inhibition of bone tumor formation using antisense cdna therapy
KR100582806B1 (ko) * 2000-05-02 2006-05-23 에프. 호프만-라 로슈 아게 신규한 감마 선택적인 레티노이드
US6740333B2 (en) * 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
US6660034B1 (en) * 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
JP2004532251A (ja) * 2001-05-31 2004-10-21 ミラヴァント ファーマシューティカルズ インコーポレイテッド 光線力学療法で使用のメタロテトラピロール系光増感剤
DE60219677T2 (de) * 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville Wasserlösliche polymerkonjugate von retinoesäure
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040122080A1 (en) * 2002-03-22 2004-06-24 Vivat-Hannah Valerie S Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
CN100360502C (zh) * 2002-07-23 2008-01-09 阿登尼亚投资有限公司 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
WO2004050101A2 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US20040138154A1 (en) * 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
US7284401B2 (en) * 2004-01-12 2007-10-23 Boston Scientific Scimed, Inc. Stent reducing system and device
US7304045B2 (en) * 2004-10-05 2007-12-04 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells
SI2727583T1 (sl) * 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
JP5237821B2 (ja) * 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
TW200918099A (en) * 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736179A (zh) * 2012-05-07 2015-06-24 日东电工株式会社 具有接头的聚合物缀合物
CN104780911A (zh) * 2012-10-30 2015-07-15 粒子科学有限公司 具有靶向部分的药物递送粒子制剂
CN106133024A (zh) * 2014-04-07 2016-11-16 日东电工株式会社 用于疏水性药物递送的新颖的基于聚合物的助水溶物
US10080737B2 (en) 2014-04-07 2018-09-25 Nitto Denko Corporation Polymer-based hydrotropes for hydrophobic drug delivery
CN106133024B (zh) * 2014-04-07 2019-07-05 日东电工株式会社 用于疏水性药物递送的新颖的基于聚合物的助水溶物
CN112004528A (zh) * 2017-12-18 2020-11-27 巴德股份有限公司 载药微珠组合物、栓塞组合物和相关方法
CN112004528B (zh) * 2017-12-18 2023-01-03 巴德股份有限公司 载药微珠组合物、栓塞组合物和相关方法
US11590080B2 (en) 2017-12-18 2023-02-28 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
US11607388B2 (en) 2017-12-18 2023-03-21 C.R. Bard, Inc. Drug-loaded microbead compositions, embolization compositions and associated methods
US12440447B2 (en) 2017-12-18 2025-10-14 C.R. Bard, Inc. Drug-loaded microbead compositions, embolization compositions and associated methods
US12558308B2 (en) 2017-12-18 2026-02-24 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents

Also Published As

Publication number Publication date
JP2016104732A (ja) 2016-06-09
RU2013146387A (ru) 2015-04-27
EP2323693B1 (en) 2017-11-08
RU2011107076A (ru) 2012-09-10
US20140212474A1 (en) 2014-07-31
WO2010014117A1 (en) 2010-02-04
KR20140065017A (ko) 2014-05-28
KR20110051214A (ko) 2011-05-17
CA2732412A1 (en) 2010-02-04
US20100028416A1 (en) 2010-02-04
RU2505315C2 (ru) 2014-01-27
EP2323693A1 (en) 2011-05-25
CA2732412C (en) 2014-12-09
AU2008359989A1 (en) 2010-02-04
JP2014129364A (ja) 2014-07-10
TW201004646A (en) 2010-02-01
ES2657214T3 (es) 2018-03-02
JP2011529492A (ja) 2011-12-08

Similar Documents

Publication Publication Date Title
RU2505315C2 (ru) Носители лекарственных средств
Ren et al. Carrier-free supramolecular hydrogel composed of dual drugs for conquering drug resistance
CN101970012A (zh) 药物载体
US11850309B2 (en) Cationic materials and formulations for drug delivery
Wang et al. Self-assembled indomethacin dimer nanoparticles loaded with doxorubicin for combination therapy in resistant breast cancer
Xue et al. Zwitterionic polypeptide-based nanodrug augments pH-triggered tumor targeting via prolonging circulation time and accelerating cellular internalization
Zhang et al. Zwitterionic targeting doxorubicin-loaded micelles assembled by amphiphilic dendrimers with enhanced antitumor performance
Chen et al. Response of pH-sensitive doxorubicin nanoparticles on complex tumor microenvironments by tailoring multiple physicochemical properties
WO2025124615A2 (zh) 一类白蛋白-紫杉醇孪药纳米粒的制备及应用
CN113171466B (zh) 一种用于治疗急性肺损伤的复合物及其制备方法与应用
RU2451509C1 (ru) Противоопухолевый препарат
JP2023522984A (ja) 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
EP3922347B1 (en) Supramolecular systems based on dynamic self-organizing nanostructures with antiviral properties
CN1839799A (zh) 一种凝集素修饰的经鼻入脑的药物传递系统
Kar et al. Protein and enzyme-based nanoformulations
HK1159504A (en) Drug carriers
CA2863307C (en) Retinoid-targeted drug carriers
WO2023191651A1 (ru) Супрамолекулярные наночастицы с противовирусными свойствами на основе бензимидазолированного гем-порфирина
CN103845737A (zh) 基于mim蛋白环肽抑制剂的靶向长循环脂质体及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1159504

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110817

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1159504

Country of ref document: HK